Literature DB >> 32971261

Identification of a 3-β-homoalanine conjugate of brusatol with reduced toxicity in mice.

Nicky Hwang1, Yonggang Pei2, Jason Clement1, Erle S Robertson3, Yanming Du4.   

Abstract

Brusatol, a quassinoid natural product, is effective against multiple diseases including hematologic malignancies, as we reported recently by targeting the PI3Kγ isoform, but toxicity limits its further development. Herein, we report the synthesis of a series of conjugates of brusatol with amino acids and short peptides at its enolic hydroxyl at C-3. A number of conjugates with smaller amino acids and peptides demonstrated activities comparable to brusatol. Through in vitro and in vivo evaluations, we identified UPB-26, a conjugate of brusatol with a L- β-homoalanine, which exhibits good chemical stability at physiological pH's (SGF and SIF), moderate rate of conversion to brusatol in both human and rat plasmas, improved mouse liver microsomal stability, and most encouragingly, enhanced safety compared to brusatol in mice upon IP administration.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Brusatol; Conjugates; Prodrugs; Toxicity

Mesh:

Substances:

Year:  2020        PMID: 32971261      PMCID: PMC7704689          DOI: 10.1016/j.bmcl.2020.127553

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  31 in total

Review 1.  Natural Products as Sources of New Drugs from 1981 to 2014.

Authors:  David J Newman; Gordon M Cragg
Journal:  J Nat Prod       Date:  2016-02-07       Impact factor: 4.050

2.  Mode of action of the antitumor compound bruceantin, an inhibitor of protein synthesis.

Authors:  L L Liao; S M Kupchan; S B Horwitz
Journal:  Mol Pharmacol       Date:  1976-01       Impact factor: 4.436

3.  Determination of brusatol in plasma and tissues by LC-MS method and its application to a pharmacokinetic and distribution study in mice.

Authors:  Nan Guo; Xiaoran Zhang; Fanlong Bu; Lei Wang; Zhanqi Cao; Chunmei Geng; Ruichen Guo; Dongmei Ren; Qing Wen
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2017-04-04       Impact factor: 3.205

Review 4.  Prodrugs: design and clinical applications.

Authors:  Jarkko Rautio; Hanna Kumpulainen; Tycho Heimbach; Reza Oliyai; Dooman Oh; Tomi Järvinen; Jouko Savolainen
Journal:  Nat Rev Drug Discov       Date:  2008-03       Impact factor: 84.694

5.  Ester Prodrugs of IHVR-19029 with Enhanced Oral Exposure and Prevention of Gastrointestinal Glucosidase Interaction.

Authors:  Julia Ma; Shuo Wu; Xuexiang Zhang; Fang Guo; Katherine Yang; Jia Guo; Qing Su; Huagang Lu; Patrick Lam; Yuhuan Li; Zhengyin Yan; William Kinney; Ju-Tao Guo; Timothy M Block; Jinhong Chang; Yanming Du
Journal:  ACS Med Chem Lett       Date:  2017-01-17       Impact factor: 4.345

6.  Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.

Authors:  Dongmei Ren; Nicole F Villeneuve; Tao Jiang; Tongde Wu; Alexandria Lau; Henry A Toppin; Donna D Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-04       Impact factor: 11.205

Review 7.  Adverse drug reactions of anticancer drugs derived from natural sources.

Authors:  Devesh Tewari; Pooja Rawat; Pawan Kumar Singh
Journal:  Food Chem Toxicol       Date:  2018-11-22       Impact factor: 6.023

8.  Targeting IDH1-Mutated Malignancies with NRF2 Blockade.

Authors:  Yang Liu; Yanxin Lu; Orieta Celiku; Aiguo Li; Qixin Wu; Yiqiang Zhou; Chunzhang Yang
Journal:  J Natl Cancer Inst       Date:  2019-10-01       Impact factor: 13.506

Review 9.  Discovery and development of natural product oridonin-inspired anticancer agents.

Authors:  Ye Ding; Chunyong Ding; Na Ye; Zhiqing Liu; Eric A Wold; Haiying Chen; Christopher Wild; Qiang Shen; Jia Zhou
Journal:  Eur J Med Chem       Date:  2016-06-13       Impact factor: 6.514

10.  Evolution of an amino acid based prodrug approach: stay tuned.

Authors:  Ivan S Krylov; Boris A Kashemirov; John M Hilfinger; Charles E McKenna
Journal:  Mol Pharm       Date:  2013-01-22       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.